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Objectives This study evaluated the safety, efficacy, and effect of MitraClip treatment on symptoms and left ventricular (LV)
remodeling in nonresponders to cardiac resynchronization therapy (CRT).
Background Moderate to severe functional mitral regurgitation (FMR) frequently persists after CRT, contributing to reduced or
no response to CRT. Percutaneous repair with the MitraClip has been proposed as an additional therapeutic op-
tion in select patients with significant FMR.
Methods Fifty-one severely symptomatic CRT nonresponders with significant FMR (grade 2, 100%) underwent MitraClip
treatment. Changes in New York Heart Association functional class, degree of FMR, LV ejection fraction (EF), and
LV end-diastolic/end-systolic volumes (EDV/ESV) before and after (3, 6, and 12 months) MitraClip implantation
were recorded. Mortality data, including cause of death, were collected.
Results MC treatment was feasible in all patients (49% 1 clip, 46% 2 clips). There were 2 periprocedural deaths. Median
follow-up was 14 months (25th to 75th percentile: 8 to 17 months). New York Heart Association functional class
improved acutely at discharge (73%) and continued to improve progressively during follow-up (regression model,
p  0.001). The proportion of patients with significant residual FMR (grade 2) progressively decreased during
follow-up (regression model, p  0.001). Reverse LV remodeling and improved LVEF were detected at 6 months,
with further improvement at 12 months (regression model, p  0.001, p  0.008, and p  0.031 for ESV, EDV,
and LVEF, respectively). Overall 30-day mortality was 4.2%. Overall mortality during follow-up was 19.9 per 100
person-years (95% confidence interval: 10.3 to 38.3). Nonsurvivors had more compromised clinical baseline con-
ditions, longer QRS duration, and a more dilated heart.
Conclusions FMR treatment with the MitraClip in CRT nonresponders was feasible, safe, and demonstrated improved func-
tional class, increased LVEF, and reduced ventricular volumes in about 70% of these study patients. (J Am Coll
Cardiol 2011;58:2183–9) © 2011 by the American College of Cardiology Foundation
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regurgitation (FMR) in the set-
ting of left ventricular (LV) dys-
function is associated with in-
creased morbidity and mortality
(1,2). Moderate to severe FMR
is common in heart failure (HF)
patients; it occurs in approxi-
mately one-third of those with
indications for cardiac resynchro-
nization therapy (CRT) (3,4).
FMR has been reported to per-
sist in about 20% to 25% of CRT
patients and, in an additional
10% to 15%, it may actually
worsen after CRT (5). In this
subset of CRT nonresponders,
reduced reverse remodeling, increased morbidity, and
increased mortality have been reported compared with
CRT patients in whom FMR is significantly reduced or
abolished (4).
Patients with significant FMR (i.e., grade 2) and
advanced LV dysfunction pose a particularly difficult man-
agement dilemma because the benefits of surgical FMR
reduction in this population have been variable, inconsis-
tent, and suboptimal (6). When surgery is performed in this
HF population, repair with undersized ring annuloplasty
rather than replacement of the mitral valve is usually
preferred; however, its safety and effectiveness have not been
well established, and the potential occurrence of valve
stenosis has been reported (7). In addition, to the best of our
knowledge, there have been no reported morbidity and
mortality data in CRT nonresponders undergoing mitral
valve surgery.
Catheter-based treatment with the MitraClip has been
proposed as an additional therapeutic option in select
patients with degenerative mitral regurgitation or FMR
(8,9); early trials demonstrated safety, mitral regurgitation
reduction, and clinical benefit. More recently, different
groups of patients have been successfully treated (10,11),
including elderly patients with significant comorbidities
such as severe LV dysfunction, renal failure, or chronic
obstructive pulmonary disease (11). These patient groups
were either underrepresented or excluded in EVEREST
(Endovascular Valve Edge-to-Edge Repair Study) I (8,9)
and II (12).
The present study reports the safety, efficacy, and the
effect of MitraClip therapy on symptoms and LV remod-
eling in CRT patients who remained highly symptomatic
despite optimal pharmacological and device therapy (i.e.,
CRT nonresponders).
Methods
Participants. PERMIT-CARE (Percutaneous Mitral Valve
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
FMR  functional mitral
regurgitation
HF  heart failure
LV  left ventricular
LVEF  left ventricular
ejection fraction
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
NYHA  New York Heart
AssociationRepair in Cardiac Resynchronization Therapy) is a prospec-tively conducted survey reporting the outcomes in 51
symptomatic CRT patients (nonresponders) consecutively
treated with the MitraClip device (Abbott Vascular Struc-
tural Heart, Menlo Park, California) at 7 European insti-
tutions. All patients were previously treated with CRT for at
least 6 months and remained classified as New York Heart
Association (NYHA) functional class III or IV despite
pharmacological optimization, with chronic moderate-to-
severe or severe FMR due to malcoaptation of mitral valve
scallops caused by LV dysfunction. The list of investigators
and institutions is presented in the Online Appendix.
A multidisciplinary team of interventional cardiologists,
HF physicians, and cardiac surgeons at each participating
center made the decision for MitraClip treatment on the
basis of current guidelines (13), mitral valve anatomy, and
surgical risk assessment. Surgical risk was based on either
the EuroSCORE (14) or the Society of Thoracic Surgeons
(STS) (15) mortality risk calculation, or based on the
presence of specific surgical risk factors not covered in these
risk models. A logistic EuroSCORE 20 or an STS score
12 defined high risk. All patients provided oral and
written consent for the procedure, and when required, the
local ethical committees approved the survey.
Device and procedure. Both the device and procedure
have been extensively described previously (8–12). Briefly,
the MitraClip system is a catheter-based system designed to
perform a double orifice repair of the mitral valve while the
heart is beating. The system includes a clip, a steerable guide
catheter, and a clip delivery system that enables positioning
and placement of the clip on the mitral valve leaflets,
resulting in permanent leaflet approximation (12). Given
the nature of this feasibility study, there was no pre-
specified end point treatment. However, there was consen-
sus among operators that procedural success was defined as
the implantation of at least 1 clip and reduction of severity
of mitral regurgitation of at least 1 grade.
Follow-up. Clinical and echocardiographic evaluation and
CRT device follow-up were performed before and after
MitraClip treatment at each participating institution. Pa-
tients were evaluated every 3 to 4 months, or more fre-
quently, if required. CRT device programming was left to
the discretion of the local electrophysiologist or HF
physician.
Echocardiographic examination. All echocardiographic
examinations were conducted at each institution and were
subsequently independently reviewed by one of the investi-
gators (S. F.) not affiliated with the institutions. In addition,
institutional self-reporting data were compared with the
independently collected data, and in case of discrepancy, an
evaluation was made by consensus. The severity of FMR
was graded according to American Society of Echocardiog-
raphy guidelines by using quantitative and qualitative meth-
ods (16,17). Systolic pulmonary artery pressure was mea-
sured using the gradient derived from the maximal velocity
of tricuspid regurgitation, adding 5 mm Hg if the inferior
vena cava had a normal diameter, or 10 mm Hg if the vena
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fraction (EF) was performed according to the biplane
Simpson’s method (18). The mitral valve orifice area was
assessed using the pressure half-time method (19).
Major cardiovascular events. Major cardiovascular events
were defined as death, myocardial infarction, emergency
cardiac surgery for adverse events, stroke, renal failure,
ventilation for 48 h, gastrointestinal complication requir-
ng surgery, new onset of permanent atrial fibrillation,
epticemia, and transfusion of 2 U of blood.
Statistical analysis. Data were described as mean  SD if
continuous, and counts and percent if categorical. Changes
over time of clinical and echocardiographic parameters were
assessed by means of a general linear model (with logistic or
identity link, as appropriate) and calculation of Huber-
White robust SEs to account for intrapatient correlation
over time. Survival was described by means of the Kaplan-
Meier curve and median follow-up with the inverse Kaplan-
Meier method. The log-rank test and Cox regression were
used to compare survival according to baseline characteris-
tics. Mortality was summarized with counts and percent-
ages. Stata version 11 (StataCorp, College Station, Texas)
was used for computation. All tests were 2-sided; p  0.05
was considered statistically significant.
Results
Study population. Demographic characteristics, pharma-
cological treatment, and baseline echocardiographic evalu-
ation (Table 1) were typical of a CRT nonresponder
population. Indeed, most patients were elderly males in an
advanced NYHA class despite pharmacological and device
optimization, had high N-terminal pro–B-type natriuretic
peptide (NT-proBNP), had ischemic heart disease and
renal disease, had been treated with a CRT system including
implantable cardioverter-defibrillator for a mean of nearly 3
years, and had a high logistic EuroSCORE and STS score,
the latter of which frequently excluded surgical options.
FMR was judged to be moderate to severe in 46% and
severe in 54% of patients. In 88% of patients, the FMR
originated in the A2/P2 region of the valve. The left
ventricle was particularly dilated (LV end-diastolic vol-
ume 238.7  72.2 ml; LV end-systolic volume 174.5 61.0
ml) and LV function was significantly depressed (LVEF
27.1  8.7%) without a meaningful improvement com-
pared with pre-CRT values (LV end-diastolic volume
220.4  70.5 ml; LV end-systolic volume 161.4  59.6
ml; LVEF 25.5  7.9%).
Procedural outcome. In most patients, FMR reduction
was achieved within 3 h of placement of either 1 clip (49%)
or 2 clips (46%). There was some degree of residual FMR in
nearly all patients, but its severity was mild or moderate
(Fig. 1); residual FMR was frequently located at A2/P2. No
clinical or echocardiographic signs of mitral stenosis were
observed. Most patients required inotropic support either
before or during the procedure (Table 2).There were 2 major adverse events at 2 different
centers. One patient died in the course of the procedure;
the patient had a low EF (33%), severe FMR, and could
not be weaned of intravenous inotropic support during
hospitalization pre- or post-MitraClip treatment. In the
Demographic Characteristics (N  51)Table 1 Demographic Characteristics (N  51)
Age (yrs) 70.26 9.16
Male 44 (86)
Etiology (%)
Ischemic cardiomyopathy 37 (73)
Nonischemic cardiomyopathy 14 (27)
Previous interventions (%)
CABG or PCI 24 (47)
Valve surgery 4 (8)
New York Heart Association functional class
III 32 (63)
IV 17 (35)
Previous CRT-D (%) 47 (92)
CRT-P 4 (8)
Comorbidities
Previous stroke 8 (16)
Diabetes 11 (22)
COPD 15 (29)
Renal insufficiency 36 (70)
Logistic EuroSCORE 29.7 19.4
STS score 13.9 14.6
Laboratory findings
Creatinine (mol/l) 149.5 63.2
Sodium (mmEq/l) 139.74 4.2
Potassium (mmEq/l) 4.25 0.41
Hemoglobin (g/dl) 12.34 1.5
NT-proBNP (ng/l) 3,702 (1,794–8,148)
Month since CRT 32.9 25.7
ECG
Sinus rhythm 18 (35)
QRS width during CRT (ms) 149.26 28.84
Echocardiography
LV end-diastolic diameter (mm) 71.0 8.7
LV end-systolic diameter (mm) 60.3 9.8
LV end-diastolic volume (ml) 238.7 72.2
LV end-systolic volume (ml) 174.5 61.0
LV ejection fraction (%) 27.1 8.7
Mitral regurgitation grade 2 51 (100)
Systolic pulmonary artery pressure (mm Hg) 44.6 11.7
Medication
ACE inhibitors or ARBs 47 (92)
Beta-blockers 45 (88)
Diuretics 50 (98)
Aldosterone antagonists 27 (53)
Statins 26 (51)
Oral anticoagulation 24 (74)
Values are mean  SD, n (%), or median (25th to 75th percentile).
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CABG  coronary
rtery bypass graft; COPD  chronic obstructive pulmonary disease; CRT  cardiac resynchroni-
ation therapy; CRT-D  cardiac resynchronization therapy with a defibrillator; CRT-P  cardiac
esynchronization therapy pacemaker; ECG  electrocardiography; LV  left ventricular; NT-
roBNP  N-terminal pro–B-type natriuretic peptide; PCI  percutaneous coronary intervention;
TS  Society of Thoracic Surgeons.other patient, chordal rupture occurred during the pro-
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emergent surgery.
Clinical and echocardiographic outcomes. At discharge,
many patients (73%) already had improved NYHA func-
tional class. The proportion of patients classified as NYHA
functional class I and II progressively increased over time
(regression model, p  0.001) (Fig. 1). Similarly, the
proportion of patients with significant residual FMR (grade
2) progressively reduced over time (regression model, p 
0.001) (Fig. 1). No patient was reported to have a significant
mitral gradient during the follow-up period.
Reverse LV remodeling was observed later in follow-up, and
the first significant change in both LV end-diastolic and
end-systolic volumes were detected 6 months after MitraClip
treatment (Fig. 2) and further reduction was observed 12
months after treatment (regression model, p 0.001 and p
0.008 for end-systolic and end-diastolic volumes, respectively).
In a similar manner, LVEF was nearly unchanged at 3 months
but significantly increased at 6 and 12 months after MitraClip
treatment (regression model, p  0.031).
Figure 1 Improvement Over Time of NYHA Functional Class and
Distributions of (A) New York Heart Association (NYHA) functional class and (B) fu
and pre- and post-MitraClip (MC) implantation (regression model, p  0.001 respe
Procedural Data and Intraprocedural ComplicationsTable 2 Procedural Data and Intraprocedural Complications
Total procedure time (min) 172.1 82.9
Total device time (min) 102.8 62.9
Fluoroscopy time (min) 31.6 18.1
Deployment of 1 clip 25 (49)
Use of inotropic drugs 35 (67)
Complications
Acute heart failure 7 (14)
Cardiac tamponade 1 (2)
Acute bleeding requiring transfusion 5 (10)
Urgent surgical valve repair/replacement 1 (2)
Death 1 (2)Values are mean  SD or n (%).Mortality and hospitalization rate. In addition to the
periprocedural mortality, 2 additional patients died 14 and
18 days after MitraClip treatment. Overall 30-day mortality
was 4.2%. Median follow-up was 14 months (25th to 75th
percentile: 8 to 17); there were 7 additional deaths during
the follow-up period. Thus, a total of 9 patients died (18%).
The most common cause of death was cardiac, occurring in
6 of 7 patients, with 1 of these 6 deaths occurring suddenly;
in this patient no autopsy and no device interrogation could
be performed. One of the 7 deaths was due to noncardiac
causes. Mortality primarily occurred within 6 months of
treatment, as demonstrated in the Kaplan-Meier curve (Fig. 3).
None of the clinical and echocardiographic characteristics
appeared to be significantly associated with survival except
for previous valvular surgery, which increased the risk of
dying by 5 (Online Table 1). However, nonsurvivors fre-
quently seemed to be older, to have more previous valvular
surgery, a much higher logistic EuroSCORE and STS,
much higher mean value of NT-proBNP, longer QRS
duration, and a more dilated heart (Online Table 1).
During follow-up, 5 patients were hospitalized: 2 patients
for acute HF decompensation and 3 patients for noncardiac
reasons.
Discussion
Main findings. The results of the PERMIT-CARE survey
confirm that significant FMR is one of the causes of clinical
nonresponse to CRT and that FMR reduction with MitraClip
treatment is feasible, safe, and leads to substantial improve-
ment in NYHA functional class and reverse ventricular remod-
eling. Although the MitraClip procedure in this population
with advanced HF carries a certain peri- and post-procedural
ral Regurgitation
al mitral regurgitation severity pre-cardiac resynchronization therapy (CRT)
).Mit
nction
ctivelymorbidity and mortality risk, it is important to note that nearly
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due to a very high estimated mortality risk.
General considerations. The results of the PERMIT-
CARE survey should be interpreted in the context of the
patient population that was treated. Patients had several
demographic characteristics that distinguish them from
typical CRT patient populations or from patients included
in mitral valve surgery series or reported patients treated
with the MitraClip device. All patients included in the
PERMIT-CARE survey can be considered nonre-
sponders to CRT because they had unchanged symptoms
and ventricular volumes after at least 6 months of CRT.
Moreover, the vast majority of patients had ischemic
cardiomyopathy, a group of CRT patients who usually
shows minor reduction in or unchanged ventricular vol-
Figure 2 Changes Over Time of Echocardiographic Parameters
Sequential changes of (A) left ventricular diameters, (B) left ventricular vol-
umes, and (C) left ventricular ejection fraction. EDD  end-diastolic diameter;
EDV  end-diastolic volume; ESD  end-systolic diameter; ESV  end-systolic
volume; other abbreviations as in Figure 1.umes at follow-up (20,21).It is well known that patients with advanced HF with
ischemic cardiomyopathy and severe FMR have a particu-
larly adverse outcome as shown by Mihaljevic et al. (6) and by
Braun et al. (22). As reported, our patients have distinct clinical
features compared with recently published series of MitraClip
patients. The EVEREST I (8,9) and the EVEREST II (12)
trials systematically excluded patients with severely de-
pressed LVEF and large ventricles, whereas Franzen et al.
(11) reported patients with a mean LVEF higher (0.36)
than ours (0.27). It is fair to state that patients included in
PERMIT-CARE may be considered patients with ex-
tremely limited, if any, other therapeutic options.
Effect of therapy on symptoms and valvular regurgitation.
MitraClip treatment significantly improved functional
NYHA class in the vast majority of CRT nonresponders.
The change over time was similar to what has been reported
in other recent MitraClip studies. In the high-risk study of
the EVEREST II trial, about 75% of patients were in
NYHA functional class I or II at discharge and at 12-month
follow-up (9). Similarly, Franzen et al. (11) reported, in a
single-center study which included 51 high-risk, signifi-
cantly symptomatic patients, that about 70% of patients
were already in NYHA functional class II or lower at
discharge. The symptomatic improvement was closely re-
lated to significant reduction in FMR severity. Residual
FMR grade 2 was present in 20% of PERMIT-CARE
patients at discharge, and this proportion decreased over
time, present in only about 10% at 1 year. This finding is
consistent with all previously reported MitraClip studies
independently of etiology of FMR (10,11), in both low- and
high-risk patient populations (10,11), in single-center ob-
servational (11) or in prospectively controlled trials (8,9).
Comparable results in FMR reduction have been reported
in surgical FMR series (22–25), showing that 6% to 10% of
surgically repaired mitral valve patients had residual FMR
grade 2; however, it should be noted, that the most
frequently treated FMR etiology in surgical series con-
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Figure 3 Kaplan-Meier Survival Estimate
Cumulative event-free survival rate in successfully treated patients.
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cardiomyopathy.
Reduction in FMR was achieved in patients in whom
FMR was unaffected by CRT. There are limited data about
the long-term evolution of FMR in CRT patients. A recent,
observational multicenter study by Di Biase et al. (4)
conducted in 794 patients with a mean follow-up of 26
months reported that, in about one-third of patients with
moderate to severe FMR, FMR severity and LV volumes
remained unchanged after CRT. Although our study does
not provide insight into the mechanisms for unchanged
FMR or worsening FMR in CRT nonresponders, it em-
phasizes the need to stratify early after CRT those patients
who may either develop FMR or in whom FMR severity is
unlikely to change as well as the need to consider additional
therapeutic options such as surgery or MitraClip treatment.
Effect of MitraClip on reverse remodeling. Evidence
suggests that the improved outcomes observed with CRT are
associated with reverse remodeling, a process characterized by
a reduction in LV volumes leading to improved systolic and
diastolic function. The structural and functional changes asso-
ciated with this process occur as early as 3 months and are even
more pronounced by 6 months, at which time the magnitude
of reverse remodeling has been shown to predict the long-term
prognosis in both medically treated patients as well as CRT
patients (21,26,27). In the PERMIT-CARE survey, changes
in both end-diastolic and end-systolic volumes after MitraClip
were clearly evident. The observation that reverse remodeling
occurred even in the presence of a moderate mitral regurgita-
tion is particularly interesting because about 60% to 70% of our
patients retained FMR of grade2 at 6 months. This finding
ay suggest that a limited change in ventricular loading
ondition could be sufficient to induce reverse remodeling in
RT nonresponders. Unfortunately, the sample size was too
mall to determine if a larger reduction in FMR after Mitra-
lip implantation may have more dramatic effects on reverse
emodeling.
ajor clinical events after MitraClip implantation. The
eriprocedural mortality rate was 5.8%, whereas the overall
ortality was 20 per 100 person-years; the most frequent
ause of death was HF. Although these rates may be
onsidered high, one should carefully consider the results in
he context of the demographic characteristics and expected
utcome of surgical treatment as well as in the context of the
natural” history of CRT nonresponders. Although the
ogistic EuroSCORE accuracy at predicting surgical mor-
ality risk in different surgical subgroups has been ques-
ioned (28), it is a commonly used score; it predicted a
9.7% perioperative mortality in the study cohort. A similar
igh perioperative mortality was predicted by the STS risk
core, thus making surgical mitral valve repair or replace-
ent unlikely. In addition, the age of our patients would
revent eligibility for a LV assist device or for cardiac
ransplantation. Compared with recent surgical series that
eported perioperative mortality ranging from 3.3% to 4.8%
29,30), the event rate observed in our cohort was similar5.8) but slightly higher, which may be explained by the fact
hat our patients were significantly older, had low EF, and
ultiple comorbidities, and primarily ischemic etiology.
he “natural” history of CRT nonresponders has been
rimarily reported in single-center, observational studies.
ccording to Ypenburg et al. (5), NYHA functional class
II CRT nonresponders have a 3-year mortality ranging
rom 35% to 70%. Therefore, even a minor reduction in
ortality combined with a significant gain in functional
apacity may be considered a major therapeutic success in
his patient cohort with advanced HF. Obviously, a properly
esigned, randomized controlled trial is needed to confirm
ur positive findings.
tudy limitations. Although this study represents the larg-
st multicenter experience with MitraClip therapy reported
o date, the total number of 51 CRT nonresponders is small,
nd a larger number of patients with adequate long-term
ollow-up is needed. This was an observational study im-
lying that changes in pharmacological therapies during
ollow-up may have influenced FMR severity, outcome, and
emodeling. However, we believe that the observational
ature of the study makes the results more representative of
eal-world clinical practice. Finally, the value of surgical
epair compared with replacement is also debatable because
MR often recurs after repair as a consequence of continued
entricular remodeling, which results in recurrent valve
enting. However, our preliminary data do not substantiate
his view for MitraClip repair, as continuous reduction in
he severity of FMR and reverse remodeling was observed.
lthough an echocardiographic protocol was not pre-
efined, all examinations were reviewed by an independent
xperienced echocardiographer, which partially mitigates
he issue of institutional variability self-reporting.
onclusions
itraClip treatment in CRT nonresponders with clinically
ignificant FMR was feasible and safe, and produced im-
roved NYHA functional class, increased LVEF, and re-
erse LV remodeling in a significant proportion of these
tudy patients. Prospective studies are warranted to confirm
ur findings and to evaluate appropriate timing of Mitra-
lip treatment after CRT.
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